Search
Daprodustat
go.drugbank.com/drugs/DB11682ApprovedInvestigationalAs a potent inhibitor of PHD1, PHD2 and PHD3 (≥ 1000-fold selectivity), daprodustat stabilizes cellular HIF1α and HIF2α and the induces erythropoiesis. … Daprodustat is a small-molecule hypoxia-inducible factor (HIF) prolyl hydroxylase (PHD) inhibitor that was developed by GSK.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 InhibitorsFolitixorin calcium
go.drugbank.com/drugs/DB05308InvestigationalANX-510 (CoFactor) is a folate-based biomodulator drug being developed to enhance the activity and reduce associated toxicity of the widely used cancer chemotherapy, 5-fluorouracil (5-FU). … CoFactor use with 5-FU is being evaluated in clinical trials in first line treatment of metastatic colorectal cancer.
Urokinase
go.drugbank.com/drugs/DB00013ApprovedInvestigationalWithdrawnUrokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. … [A191943] Urokinase remains connected between these 2 chains by a sulfhydryl bond.[A191943] Urokinase was granted FDA approval on 16 January 1978.[L12138]
Products: UROKINASE-GREEN CROSS INJ. 60,000 iu/vial, UROKINASE KGCC INJ. 250000 IU FLAKON, 1 ADETVamorolone
go.drugbank.com/drugs/DB15114ApprovedInvestigational[L48671,L48676] In December 2023, it was approved in the EU for the treatment of patients ≥4 years of age.[L49505] … [L48676] Vamorolone is positioned as having a more tolerable adverse effect profile than other corticosteroids owing to its unique receptor binding profile,[A261976] thus providing an additional treatment
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersEnasidenib
go.drugbank.com/drugs/DB13874ApprovedInvestigationalThis small molecule acts as an allosteric inhibitor of mutant IDH2 enzyme to prevent cell growth, and it also has shown to block several other enzymes that play a role in abnormal cell differentiation. … gene, which is a recurrent mutation detected in 12-20% of adult patients with AML [A20344, A20345].
Categories: Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic IndexSodium hydroxide
go.drugbank.com/drugs/DB11151ApprovedSodium hydroxide is generally used as a solid or a diluted in a 50% solution. This chemical is used to manufacture soaps, rayon, paper, explosives, dyestuffs, and petroleum products [L1965]. … According to the the FDA, sodium hydroxide is considered a direct food recognized as safe, where it serves as a pH control agent and follows good manufacturing guidelines [L1967].
Mixtures: CLINDAMICINA 600 MG / 4 ML SOLUCIÓN INYECTABLE, NUTRIFLEX LIPID PLUS INFUZYONLUK EMULSIYON, 1250 MLCategories: Compounds used in a research, industrial, or household settingVaricella zoster vaccine (recombinant)
go.drugbank.com/drugs/DB13924ApprovedInvestigationalpatients 50-70 years of age [FDA Label]. … First approved in October 2017 by the Food and Drug Administration, Shingrix is the preferred vaccine for preventing varicella zoster infection in people aged 50 years and older, replacing Zostavax as
RPI-78M
go.drugbank.com/drugs/DB05740ExperimentalOther neurological disorders that may be served by RPI-78M include myasthenia gravis (MG), muscular dystrophy (MD) and amyotrophic lateral sclerosis (ALS). … RPI-78M is being developed for the treatment of multiple sclerosis (MS).
Avapritinib
go.drugbank.com/drugs/DB15233ApprovedInvestigational[A189327] Avapritinib shares a similar mechanism with [ripretinib]. Avapritinib was granted FDA approval on 9 January 2020 [L40363] and EMA approval on 24 September 2020.[L41464] … Avapritinib, or BLU-285,[A189327] is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 InhibitorsAcetrizoic acid
go.drugbank.com/drugs/DB09347ApprovedWithdrawn[A32135] It was first synthesized by Wallingford in 1953[A32136] and it was filled in the FDA by the Johnson & Johnson subsidiary, Cilag Chemie AG, on February 8th, 1978. … [L1704] Acetrizoic acid presents, in the FDA records, a category of drug substance with an inactive status.[L1703]
Categories: Compounds used in a research, industrial, or household setting